- Home
- AMWL vs ZNTL Comparison
AMWL vs ZNTL Comparison
Compare AMWL & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMWL
- ZNTL
- Stock Information
- Founded
- AMWL 2006
- ZNTL 2014
- Country
- AMWL United States
- ZNTL United States
- Employees
- AMWL N/A
- ZNTL N/A
- Industry
- AMWL Retail: Computer Software & Peripheral Equipment
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- AMWL Technology
- ZNTL Health Care
- Exchange
- AMWL Nasdaq
- ZNTL Nasdaq
- Market Cap
- AMWL 121.9M
- ZNTL 102.2M
- IPO Year
- AMWL 2020
- ZNTL 2020
- Fundamental
- Price
- AMWL $6.88
- ZNTL $1.23
- Analyst Decision
- AMWL Hold
- ZNTL Buy
- Analyst Count
- AMWL 6
- ZNTL 8
- Target Price
- AMWL $10.00
- ZNTL $8.53
- AVG Volume (30 Days)
- AMWL 58.2K
- ZNTL 752.0K
- Earning Date
- AMWL 05-01-2025
- ZNTL 05-20-2025
- Dividend Yield
- AMWL N/A
- ZNTL N/A
- EPS Growth
- AMWL N/A
- ZNTL N/A
- EPS
- AMWL N/A
- ZNTL N/A
- Revenue
- AMWL $261,675,000.00
- ZNTL $67,425,000.00
- Revenue This Year
- AMWL $2.28
- ZNTL N/A
- Revenue Next Year
- AMWL $10.06
- ZNTL N/A
- P/E Ratio
- AMWL N/A
- ZNTL N/A
- Revenue Growth
- AMWL 2.79
- ZNTL N/A
- 52 Week Low
- AMWL $5.00
- ZNTL $1.01
- 52 Week High
- AMWL $12.95
- ZNTL $13.24
- Technical
- Relative Strength Index (RSI)
- AMWL 44.58
- ZNTL 38.08
- Support Level
- AMWL $6.42
- ZNTL $1.33
- Resistance Level
- AMWL $7.15
- ZNTL $1.32
- Average True Range (ATR)
- AMWL 0.61
- ZNTL 0.10
- MACD
- AMWL 0.00
- ZNTL -0.00
- Stochastic Oscillator
- AMWL 36.28
- ZNTL 8.22
About AMWL American Well Corporation
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.